GUIDE: A Randomized Non-Comparative Phase II Trial of Biomarker-Driven Intermittent Docetaxel Versus Standard-of-care Docetaxel in Metastatic Castration-Resistant Prostate Cancer (ANZUP 1903).
JOURNAL OF CLINICAL ONCOLOGY(2023)
Key words
Metastatic Prostate Cancer
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined